Gene Therapy Trial for Type 1 Diabetes Set to Launch This Year
A pioneering gene therapy trial for type 1 diabetes is scheduled to commence this year, igniting optimism that a single injection could revolutionise treatment for millions globally. Adults diagnosed with this incurable condition will receive a one-time dose of KRIYA-839, an innovative injection designed to enable the body to regulate blood sugar levels autonomously, eliminating the necessity for daily insulin administration.
Early Success and Human Testing
Initial trials involving animal models demonstrated that the injection remained effective for up to four years without compromising the immune system. This breakthrough was officially presented at the International Conference on Advanced Technologies and Treatments for Diabetes. The therapy is now poised for its inaugural human trials, with the potential to deliver lifelong benefits.
Jeremy Pettus, an endocrinologist and associate professor of medicine at the University of California, expressed his enthusiasm, stating, "In the type 1 community, we're accustomed to hearing promises that might materialise in a decade or more. It's incredibly thrilling to announce that this is actively progressing and happening now." His remarks were initially reported by Medscape.
Mechanism and Potential Impact
The therapy aims to transform thigh muscles, where the injection is administered, into insulin-producing sites that assist in blood sugar regulation. Dr Partha Kar, NHS England's national speciality adviser for diabetes, described the development as "truly exciting" and highlighted its potential as a "functional cure" for the condition. He emphasised that this could alleviate the daily burden faced by patients.
Professor Pettus clarified that the method does not involve gene editing or altering genetic makeup. Instead, it delivers insulin-related genes into muscle cells, where they persist and continuously produce proteins over the long term. He noted, "This technology is well-established. Advances in manufacturing now allow us to extend its application from rare conditions to more prevalent diseases like diabetes."
Current Landscape and Future Prospects
Approximately 464,000 individuals in the UK live with type 1 diabetes, a condition characterised by the body's inability to produce insulin, a hormone essential for converting sugar into energy. Currently, patients depend on daily insulin injections or pumps to manage their blood sugar levels. This new therapy could substantially reduce this burden worldwide, with Professor Pettus suggesting it might eventually become accessible to the masses.
Dr Kar remarked that the injection has the potential to "assist numerous people if successful" and could serve as a functional cure, even if not a complete one. He added, "I view this as highly promising. We're discussing the possibility of eliminating high insulin doses or reliance on artificial systems. Ultimately, this represents a significant technological advancement."
Trial Details and Cautious Optimism
Dr Kar identified two primary uncertainties for the trials: the quantity of insulin the injection will generate and the duration of its effects. He speculated, "If it can fulfil 75 per cent of insulin requirements, that would be a monumental achievement. I remain optimistic and would closely monitor this if I or my children had type 1 diabetes."
The treatment includes a brief phase of immune modulation, temporarily suppressing the immune system to facilitate effective cell entry. Administered in both legs during a single outpatient visit lasting up to an hour, the injection may require two to three months to achieve full efficacy. Professor Pettus affirmed, "If all proceeds smoothly, this could endure for the patient's entire lifetime."
The initial trial will span one year and enrol adults with elevated blood sugar levels who already utilise automated insulin delivery systems, enabling researchers to track changes meticulously. Success could lead to future trials incorporating individuals who rely on daily injections.
Tadej Battelino, head of endocrinology at UCH-UMC Ljubljana, advised caution, stating, "I hesitate to use the term 'cure' prematurely. While the potential is substantial, I refrain from making guarantees." He acknowledged that if the therapy can maintain blood sugar within a healthy range, possibly in conjunction with technology, it might qualify as a functional cure.
